| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9290954316e579acbf4ecb22acc379e6 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-156
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-495
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4184
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4184
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-495 |
| filingDate |
2015-10-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cdb08864a7e42b543f1b1c5be3d2904d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d1d704a4d4cd46c0d125b9d646794256
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_42d20992a3e61dd118de48983834bd64
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_83b58a5a1e8c5beef391dfa4bb6c657f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_533b4f877bf17bf765d44b3119fa533c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f58a3969a3a0f5bf1e201358e2320c23 |
| publicationDate |
2017-11-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2017342498-A1 |
| titleOfInvention |
Parp genomic variants conferring resistance and sensitization to chemotherapy under inhibition |
| abstract |
A method is provided for selecting a subject diagnosed with cancer as a candidate for treatment with a PARP1 inhibitor, or both a PARP1 inhibitor and a chemotherapeutic agent such as an alkylating agent. The method includes detecting the presence or absence of a mutation in a non-coding region of a PARP1 gene, wherein the presence of a mutation in the PARP1 gene indicates that the cancer can be treated with the PARP1 inhibitor, optionally in conjunction with the chemotherapeutic agent. In a specific, non-limiting example, the PARP1 inhibitor is verliparib (ABT-888). |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023133409-A3 |
| priorityDate |
2014-11-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |